Mehmet E. Kalender
Turkey
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG).
Journal: Cancers
Published: February 12, 2026
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis.
Journal: Journal of clinical medicine
Published: February 01, 2026
Sensitivity, Specificity, and Accuracy of Ultrasound, Mammography, and 18F-FDG PET/CT in Diagnosing Breast Cancer Metastasis to Axillary Lymph Nodes: A Single-Center Experience.
Journal: Medicina (Kaunas, Lithuania)
Published: December 23, 2025
Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group.
Journal: Frontiers in oncology
Published: November 28, 2025
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer.
Journal: Scientific reports
Published: July 25, 2024
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Journal: BMC cancer
Published: February 28, 2023
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Journal: BMC cancer
Published: September 15, 2022
Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Journal: Journal of gastrointestinal cancer
Published: October 08, 2016
Polymorphisms in the MTHFR gene are associated with recurrence risk in lymph node-positive breast cancer patients.
Journal: OncoTargets and therapy
Published: September 28, 2016
Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.
Journal: OncoTargets and therapy
Published: August 31, 2016
Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study.
Journal: OncoTargets and therapy
Published: April 22, 2016
Last Updated: 09/26/2026